journal
MENU ▼
Read by QxMD icon Read
search

Biologics: Targets & Therapy

journal
https://www.readbyqxmd.com/read/27853353/update-on-sepsis-associated-acute-kidney-injury-emerging-targeted-therapies
#1
REVIEW
James F Doyle, Lui G Forni
Sepsis-associated acute kidney injury (SA-AKI) is an independent predictor of increased mortality and morbidity. It is essential that further advances in the treatment of sepsis should prioritize targeted therapies in SA-AKI in order to improve these bleak outcomes. As yet, a unique therapy that effectively reduces the impact of acute kidney injury has not been demonstrated. However, the emergence of novel targeted therapies, perhaps in combination, has the possibility of significantly reducing the long-term sequelae of an episode of SA-AKI...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/27703327/eag1-channels-as-potential-early-stage-biomarkers-of-hepatocellular-carcinoma
#2
María de Guadalupe Chávez-López, Violeta Zúñiga-García, Julio Isael Pérez-Carreón, Arturo Avalos-Fuentes, Yesenia Escobar, Javier Camacho
Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide. HCC is usually asymptomatic at potential curative stages, and it has very poor prognosis if detected later. Thus, the identification of early biomarkers and novel therapies is essential to improve HCC patient survival. Ion channels have been proposed as potential tumor markers and therapeutic targets for several cancers including HCC. Especially, the ether à-go-go-1 (Eag1) voltage-gated potassium channel has been suggested as an early marker for HCC...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/27672308/therapeutic-efficacy-of-monthly-subcutaneous-injection-of-daclizumab-in-relapsing-multiple-sclerosis
#3
REVIEW
Stanley Cohan
Despite the availability of multiple disease-modifying therapies for relapsing multiple sclerosis (MS), there remains a need for highly efficacious targeted therapy with a favorable benefit-risk profile and attributes that encourage a high level of treatment adherence. Daclizumab is a humanized monoclonal antibody directed against CD25, the α subunit of the high-affinity interleukin 2 (IL-2) receptor, that reversibly modulates IL-2 signaling. Daclizumab treatment leads to antagonism of proinflammatory, activated T lymphocyte function and expansion of immunoregulatory CD56(bright) natural killer cells, and has the potential to, at least in part, rectify the imbalance between immune tolerance and autoimmunity in relapsing MS...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/27536062/new-targeted-treatments-for-non-small-cell-lung-cancer-role-of-nivolumab
#4
REVIEW
Giulia Zago, Mirte Muller, Michel van den Heuvel, Paul Baas
Non-small-cell lung cancer (NSCLC) is often diagnosed at an advanced stage of disease, where it is no longer amenable to curative treatment. During the last decades, the survival has only improved significantly for lung cancer patients who have tumors harboring a driver mutation. Therefore, there is a clear unmet need for effective therapies for patients with no mutation. Immunotherapy has emerged as an effective treatment for different cancer types. Nivolumab, a monoclonal inhibitory antibody against PD-1 receptor, can prolong survival of NSCLC patients, with a manageable toxicity profile...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/27462140/neutralizing-activities-of-human-immunoglobulin-derived-from-donors-in-japan-against-mosquito-borne-flaviviruses-japanese-encephalitis-virus-west-nile-virus-and-dengue-virus
#5
Mikihiro Yunoki, Takeshi Kurosu, Ritsuko Kubota Koketsu, Kazuo Takahashi, Yoshinobu Okuno, Kazuyoshi Ikuta
Japanese encephalitis virus (JEV), West Nile virus (WNV), and dengue virus (DenV) are causal agents of Japanese encephalitis, West Nile fever, and dengue fever, respectively. JEV is considered to be indigenized and widespread in Japan, whereas WNV and DenV are not indigenized in Japan. Globulin products seem to reflect the status of the donor population according to antivirus neutralization activity. However, the anti-JEV, -WNV, and -DenV neutralization activities of globulin products derived from donors in Japan have not been clarified...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/27462139/guanine-nucleotide-exchange-factor-h1-can-be-a-new-biomarker-of-melanoma
#6
Jie Shi, Bingyu Guo, Yu Zhang, Qiang Hui, Peng Chang, Kai Tao
Guanine nucleotide exchange factor H1 (GEF-H1), which couples microtubule dynamics to RhoA activation, is a microtubule-regulated exchange factor. Studies have shown that GEF-H1 can be involved in various cancer pathways; however, the clinical significance of GEF-H1 expression and functions in melanoma has not been established. In this study, we investigated the relationship between clinical outcomes and GEF-H1 functions in melanoma. A total of 60 cases of different grades of melanoma samples were used to detect the expression of GEF-H1...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/27307702/effects-of-fucoidan-from-fucus-vesiculosus-in-reducing-symptoms-of-osteoarthritis-a-randomized-placebo-controlled-trial
#7
Stephen P Myers, Ann M Mulder, Don G Baker, Shelley R Robinson, Margaret I Rolfe, Lyndon Brooks, J Helen Fitton
PURPOSE: Preliminary investigation of a fucoidan with demonstrated reduction in the symptoms of osteoarthritis (OA) of the hip and knee. PATIENTS AND METHODS: A double-blind randomized controlled trial was carried out to determine the safety and efficacy of a 300 mg dose of a Fucus vesiculosus extract (85% fucoidan) over a 12-week period in a population (n=122) with mild-to-moderate OA of the hip and knee as measured by the validated instrument "Comprehensive Osteoarthritis Test...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/27110096/efficacy-of-anti-il-1-treatment-in-familial-mediterranean-fever-a-systematic-review-of-the-literature
#8
Jeroen Ch van der Hilst, Michel Moutschen, Peter E Messiaen, Bernard R Lauwerys, Steven Vanderschueren
INTRODUCTION: In 5%-10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%-10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs may be an alternative for these patients, although it is not reimbursed for this indication in many countries. METHODS: We systematically searched PubMed, Web of Science, and Scopus for reports of anti-IL-1 treatment in FMF patients...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/27099470/cost-effectiveness-of-routine-measuring-of-serum-drug-concentrations-and-anti-drug-antibodies-in-treatment-of-rheumatoid-arthritis-patients-with-tnf-%C3%AE-blockers
#9
Juha Laine, T Sakari Jokiranta, Kari K Eklund, Merja Väkeväinen, Kari Puolakka
Monitoring of anti-drug antibodies (ADAbs) or serum concentrations of biologicals in treatment of rheumatoid arthritis could provide an explanation for a loss of efficacy and help in the choice of subsequent medication. Current clinical practices do not generally include such monitoring of tumor necrosis factor (TNF)-α blockers on a routine basis. The main aims of this study were to estimate the probabilities of optimal and nonoptimal treatment decisions if infliximab or adalimumab drug trough level (DL) and ADAbs are tested or not in rheumatoid arthritis, and to model cost-effectiveness of performing such monitoring on a routine basis...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/27069354/tocilizumab-in-refractory-rheumatoid-arthritis-long-term-efficacy-safety-and-tolerability-beyond-2-years
#10
Ziad Farah, Sabreen Ali, Fiona Price-Kuehne, Charles G Mackworth-Young
OBJECTIVES: To evaluate the long-term efficacy and safety of tocilizumab (TCZ) in clinical patients with rheumatoid arthritis (RA) refractory to synthetic disease-modifying antirheumatic drugs, anti-tumor necrosis factor agents, and B-cell depletion therapy with rituximab (RTX). METHODS: We conducted a single-center retrospective study of 22 patients with RA treated with TCZ. We collected data including demographics and medication histories. We recorded clinical parameters including tender joint counts and swollen joint counts, and laboratory parameters including inflammatory makers and lipid profiles over regular intervals of TCZ treatment...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/27041992/correlations-between-immunogenicity-drug-levels-and-disease-activity-in-an-italian-cohort-of-rheumatoid-arthritis-patients-treated-with-tocilizumab
#11
Maurizio Benucci, Francesca Meacci, Valentina Grossi, Maria Infantino, Mariangela Manfredi, Emanuele Bellio, Valerio Bellio, Francesca Li Gobbi, Laura Bazzichi, Paolo Moscato, Dario Caputo, Gianantonio Saviola, Rossella Talotta, Piercarlo Sarzi-Puttini, Fabiola Atzeni
The aim of this study was to evaluate the real-life immunogenicity of anti-drug antibodies, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab (TCZ). We evaluated 126 TCZ-treated patients with rheumatoid arthritis (16 males and 110 females; mean age 59±12 years, range 26-83; mean disease duration 11±5 years) with inadequate 12-week response to any synthetic and biological disease-modifying anti-rheumatic drugs, in a retrospective analysis. One-hundred and seven patients were treated with methotrexate mean dose 12...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/27022240/selective-biologics-for-ulcerative-colitis-and-crohn-s-disease-clinical-utility-of-vedolizumab
#12
REVIEW
Jill Mv Petkau, Bertus Eksteen
Inflammatory bowel disease (IBD) encompasses a cluster of different disease phenotypes which are broadly classified into ulcerative colitis and Crohn's disease. Disease pathogenesis is driven by abnormal host immune responses to their resident gut microbiome in genetically susceptible individuals. Clinical disease features and outcomes are heterogenous and not unexpected as over 163 genetic loci are associated with disease susceptibility, and there are great variability in environmental exposures. Despite this variability, there has been relatively few efficacious therapies for particularly moderate-to-severe IBD...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/27013862/update-on-the-management-of-philadelphia-chromosome-positive-chronic-myelogenous-leukemia-role-of-nilotinib
#13
REVIEW
Josephine Emole, Taiwo Talabi, Javier Pinilla-Ibarz
Chronic myelogenous leukemia (CML) is a pluripotent stem cell disease characterized by the presence of the Philadelphia chromosome and the bcr-abl gene. The discovery of tyrosine kinase inhibitors (TKIs) revolutionized therapy for CML, such that durable response, increased overall survival, and increased progression-free survival of patients in chronic phase CML is now possible. Due to resistance and intolerance to imatinib, there was need for development of second- and third-generation TKIs for the treatment of CML...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/26937170/biosimilars-in-the-management-of-neutropenia-focus-on-filgrastim
#14
REVIEW
Désirée Caselli, Simone Cesaro, Maurizio Aricò
Advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet, the price may be a proportion of patients dying of complications due to treatment-induced infectious complications, such as neutropenia. With the aim of decreasing morbidity and mortality related to infectious complications, recombinant human granulocyte colony-stimulating factor (G-CSF), filgrastim, and pegylated filgrastim have been used to reduce time and degree of neutropenia. A biosimilar is a copy of an approved original biologic medicine whose data protection has expired...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/26869762/emerging-treatments-in-castleman-disease-a-critical-appraisal-of-siltuximab
#15
REVIEW
Jean L Koff, Sagar Lonial
Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of CD is fueled by excessive interleukin-6 (IL-6) has led to considerable interest in therapeutic targeting of this cytokine. Siltuximab, a chimeric monoclonal antibody to IL-6, has thus emerged as a promising treatment option in a disease lacking efficacious therapy. Here, we review the findings of recent studies evaluating single-agent siltuximab treatment in CD, including the first-ever randomized clinical trial in this disease...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/26858523/lipegfilgrastim-in-the-management-of-chemotherapy-induced-neutropenia-of-cancer-patients
#16
REVIEW
Roberto Guariglia, Maria Carmen Martorelli, Rosa Lerose, Donatella Telesca, Maria Rita Milella, Pellegrino Musto
Neutropenia and febrile neutropenia (FN) are frequent and potentially fatal toxicities of myelosuppressive anticancer treatments. The introduction of granulocyte colony-stimulating factors (G-CSFs) in clinical practice has remarkably reduced the duration and severity of neutropenia, as well as the incidence of FN, thus allowing the administration of chemotherapeutic agents at the optimal dose and time with lower risk. The current scenario of G-CSFs in Europe includes filgrastim, lenograstim, some G-CSF biosimilars, and pegfilgrastim...
2016: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/26604681/advanced-basal-cell-carcinoma-the-hedgehog-pathway-and-treatment-options-role-of-smoothened-inhibitors
#17
REVIEW
Leslie A Fecher, William H Sharfman
Cutaneous basal cell carcinoma (BCC) is the most common human cancer and its incidence is rising worldwide. Ultraviolet radiation exposure, including tanning bed use, as well as host factors play a role in its development. The majority of cases are treated and cured with local therapies including surgery. Yet, the health care costs of diagnosis and treatment of BCCs in the US is substantial. In the United States, the cost of nonmelanoma skin cancer care in the Medicare population is estimated to be US$426 million per year...
2015: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/26604680/drug-usage-analysis-and-health-care-resources-consumption-in-na%C3%A3-ve-patients-with-rheumatoid-arthritis
#18
Diego Sangiorgi, Maurizio Benucci, Carmela Nappi, Valentina Perrone, Stefano Buda, Luca Degli Esposti
OBJECTIVES: The use of biologic agents has revolutionized the management of rheumatoid arthritis (RA) in the past 2 decades. These biologic agents directly target molecules and cells involved in the pathogenesis of RA. The purpose of this study was to assess the usage of biologic agents in terms of persistence to treatment, dose escalation, and consumption of health care resources (hospitalizations, drugs, and outpatients service) in the real clinical practice in naïve patients with RA...
2015: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/26604679/use-of-anti-tnfs-for-difficult-to-treat-urticaria-response-to-cooke-et-al
#19
Simon Francis Thomsen, Freja Lærke Sand
No abstract text is available yet for this article.
2015: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/26491251/role-of-collagenase-clostridium-histolyticum-in-peyronie-s-disease
#20
REVIEW
Taylor C Peak, Gregory C Mitchell, Faysal A Yafi, Wayne J Hellstrom
Peyronie's disease is a localized connective tissue disease characterized by an active, inflammatory phase and a stable, quiescent phase, with the eventual development of collagenous plaques within the tunica albuginea of the penis. Risk factors primarily associated with Peyronie's disease include Dupuytren's contracture, penile trauma, and family history. A variety of treatment strategies have been utilized, including oral and topical agents, electromotive drug administration, intralesional injections, extracorporeal shockwave therapy, penile traction, and surgery...
2015: Biologics: Targets & Therapy
journal
journal
41818
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"